Dulanermin - Shanghai GeBaiDe

Drug Profile

Dulanermin - Shanghai GeBaiDe

Alternative Names: Apo2L/TRAIL - Shanghai GeBaiDe; recombinant human apoptosis-2 ligand - Shanghai Qiaer; Recombinant Human TRAIL/Apo2L - Shanghai GeBaiDe; Rh-Apo2L; TNFSF10

Latest Information Update: 23 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Qiaer Bio-Technology
  • Developer Shanghai GeBaiDe Biotechnical Co
  • Class Antineoplastics; Recombinant proteins
  • Mechanism of Action Apoptosis stimulants; TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer

Most Recent Events

  • 01 Oct 2016 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater, Recurrent) in China (IV) (NCT03083743)
  • 17 Apr 2016 Biomarkers information updated
  • 11 Feb 2016 No recent reports on development identified - Phase-III for Non-small cell lung cancer (Combination therapy, Late-stage disease, Locally recurrent) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top